

CORRECTED VERSION

(19) World Intellectual Property
Organization
International Bureau



(10) International Publication Number
WO 2016/046260 A8

(43) International Publication Date
31 March 2016 (31.03.2016)

(51) International Patent Classification:
C07D 401/04 (2006.01) *A61P 19/02* (2006.01)
A61K 31/4439 (2006.01)

(21) International Application Number:
PCT/EP2015/071862

(22) International Filing Date:
23 September 2015 (23.09.2015)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
62/055822 26 September 2014 (26.09.2014) US

(71) Applicant: **ASTRAZENECA AB** [SE/SE]; S-151 85
Södertälje (SE).

(72) Inventors: **RIPA, Lena, Elisabeth**; AstraZeneca, SE-431
83 Mölndal (SE). **LAWITZ, Karolina**; c/o AstraZeneca
Intellectual Property AstraZeneca, Macclesfield Cheshire
SK10 4TG (GB). **LEPISTÖ, Matti, Juhani**; AstraZeneca,
SE-431 83 Mölndal (SE). **HEMMERLING, Martin**; As-
traZeneca, SE-431 83 Mölndal (SE). **EDMAN, Karl**; As-
traZeneca, SE-431 83 Mölndal (SE). **LLINAS, Antonio**;
AstraZeneca, SE-431 83 Mölndal (SE).


(74) Agent: **LOWRY, Rachel**; ASTRAZENECA INTELLEC-
TUAL PROPERTY, AstraZeneca Alderley Park, Maccles-
field Cheshire SK10 4TG (GB).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY,
BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR,
KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG,
MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM,
PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC,
SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ,
TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU,
TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE,
DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU,
LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK,
SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ,
GW, KM, ML, MR, NE, SN, TD, TG).

[Continued on next page]

(54) Title: 1-ALKYL-6-OXO-1,6-DIHYDROPYRIDIN-3-YL COMPOUNDS AND USE AS SGRM MODULATORS



(I)

(57) Abstract: This specification generally relates to 1-alkyl-6-oxo-1,6-dihydropyridin-3-yl compounds (including salts thereof). This specification also relates to pharmaceutical compositions and kits comprising such a compound, uses of such a compound (including treatment methods and medicament preparations), and processes for making such a compound.



Published:

— with international search report (Art. 21(3))

(15) Information about Correction:

see Notice of 13 April 2017

(48) Date of publication of this corrected version:

13 April 2017